原始出處紀錄
決策級主要結果 (Topline)
AVTX-009 第二期 LOTUS 試驗於 HS：預計 2026 年第二季公布頂線數據
Avalo 已完成 AVTX-009 在化膿性汗腺炎的第二期 LOTUS 試驗收案。頂線結果現指引為 2026 年第二季公布，確立該資產的下一個法規／臨床里程碑。
關鍵事實
來源摘錄
EX-99.1 2 ex-991_dec2025xavalocorp.htm EX-99.1 ex-991_dec2025xavalocorp ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation,